louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02916082: Cervical Length Pre-induction as a Tool to Predict Vaginal Birth
Official title: Use of Cervical Length Previous to the Use of Prostaglandins as a Tool to Predict Vaginal Birth in Pregnancies With > 41 Weeks Gestation.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cervical Length Measurement
Pregnancy, Prolonged
Keywords: Cervical length
Prolonged pregnancy
Vaginal birth
Lead sponsor: Saint Thomas Hospital, Panama
Sponsor class: OTHER
First posted: 2016-09-27
Enrollment: 200
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Pregnancies with a gestational age of 41 weeks or more.

Brief summary: To evaluate the value of measuring cervical length as a predictor of vaginal birth after induction of labor with prostaglandins in pregnancies with 41 weeks of gestation.


Eligibility criteria: Inclusion Criteria:

* 41 weeks or more of gestational age
* Cervical length measured by a FMF certified physician

Exclusion Criteria:

* Any condition that could interfere with a possible vaginal birth (previous cesarean section, hypertensive disorders of pregnancies).

Primary outcomes:
measure: Vaginal Birth
timeFrame: 72 hours
Secondary outcomes:
measure: Induction to delivery time
timeFrame: 72 hours
Other outcomes:
Locations:
city: Panama
country: Panama
facility: Saint Thomas H
Study officials:
References:
Clinical trial NCT03658382: Virtual Visits for Results Disclosure
Official title: Randomized Controlled Trial Evaluating Patient Satisfaction With Virtual Visits for Results Disclosure in the Brigham and Women's Hospital Cardiovascular Genetics Program
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Genetic Disease
Lead sponsor: Brigham and Women's Hospital
Sponsor class: OTHER
First posted: 2018-09-05
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: As part of this study patients who have undergone genetic testing in the Brigham and Women's Hospital Cardiovascular Genetics program will be randomized to receive the results of their genetic testing either by telephone call or virtual visit. At the completion of the telephone call or virtual visit patients will receive a survey to assess their understanding of their results and their satisfaction with their care.


Eligibility criteria: Inclusion Criteria:

* 18 years or older
* Undergoing genetic testing at BWH Cardiovascular Genetics clinic

Exclusion Criteria:

* Reside outside of Massachusetts
* Telephone or internet access unavailable

Primary outcomes:
measure: Patient satisfaction
timeFrame: within 7 days of results disclosure
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT07020182: Efficacy Of Inpatient Pulmonary Rehabilitation Program In Elderly Patients With Acute Exacerbation Of COPD
Official title: Efficacy Of Inpatient Pulmonary Rehabilitation Program In Elderly Patients With Acute Exacerbation Of COPD
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: COPD Received PR
Elderly (People Aged 65 or More)
COPD
COPD Acute Exacerbation
Keywords: Elderly patients with acute exacerbation of COPD
Lead sponsor: Al-Azhar University
Sponsor class: OTHER
First posted: 2025-06-13
Enrollment: 60
Sex: ALL
Minimum age (years): 65
Maximum age (years): 78
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: A prospective supervised RCT (Randomized Controlled Trial) will be done include elderly COPD patients assigned randomly into two groups; Group A performed physical therapy program, and Group B is control group completed two daily sessions from day 1 of hospital admission till discharge from the hospital.The study duration will be 12 weeks
Primary purpose: TREATMENT

Brief summary: The study aimed to identify the effect of early pulmonary rehabilitation in elderly patients with Acute exacerbation (AE) of COPD (AECOPD) in exercise tolerance, dyspnea, sleep quality, fatigue, and time to discharge from hospital.

Detailed description: A prospective supervised RCT (Randomized Controlled Trial) will be done include elderly COPD patients assigned randomly into two groups; Group A performed Physical therapy program, and Group B is control group completed two daily sessions from day 1 of hospital admission till discharge from the hospital .The study duration will be 12 weeks

Eligibility criteria: Inclusion Criteria:

* Patients with acute exacerbation of COPD in both gender
* Patient older than 65 years
* Patient with clear consciousness
* Patients had been diagnosed with shortness of breath or dyspnea that was not caused by heart disease, pneumothorax, or pulmonary edema

Exclusion Criteria:

* Patient with systolic blood pressure lower than 90 mmHg
* Patient with an unstable psychological status, hemoptysis, pneumothorax, pulmonary edema

Primary outcomes:
measure: Exercise tolerance
timeFrame: The study will be start from day 1 of hospital admission till discharge from the hospital.The study duration will be 12 weeks
Secondary outcomes:
measure: Dyspnea
timeFrame: The study will be start from day 1 of hospital admission till discharge from the hospital.The study duration will be 12 weeks
measure: Length of hospital stay(LOS)
timeFrame: The study will be start from day 1 of hospital admission till discharge from the hospital.The study duration will be 12 weeks
measure: Fatigue level
timeFrame: The study will be start from day 1 of hospital admission till discharge from the hospital.The study duration will be 12 weeks
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Faculty of Medicine for Girls- Al-Azhar-University, Cairo, Egypt
Study officials:
affiliation: Al-Azhar University
name: Mohammed, phd
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06162182: Comparative Evaluation of an Electrical Impedance Device Versus Digital Radiography in Estimation of Remaining Dentin Thickness
Official title: Comparative Evaluation of an Electrical Impedance Device Versus Digital Radiography in Estimation of Remaining Dentin Thickness in Carious Posterior Permanent Teeth (Diagnostic Accuracy Trial)
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Caries,Dental
Deep Caries
Keywords: electrical impedance device (prepometer)
digital radiography
remaining dentin thickness
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2023-12-08
Enrollment: 67
Sex: ALL
Minimum age (years): 12
Maximum age (years): 25
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: The research question was that in patients with carious posterior permanent teeth, would the electrical impedance device be as valid as digital radiography in estimation of remaining dentin thickness? The proposed hypothesis was null.


Eligibility criteria: Inclusion Criteria:

* Participants eligible for this study were those aged from 18 y to 28 y,
* willing to join the study
* with clinically detectable occlusal or proximal carious vital permanent molar teeth with closed apex and healthy periodontal supporting.
* The minimum extension of the carious cavity should be at least 1 mm in width to accommodate with the probe of the prepometer

Exclusion Criteria:

* Excluded participants were those with poor oral hygiene,
* severe medical complications,
* showing signs and symptoms of irreversible or necrotic pulp pathology also when the affected tooth was with extended buccal or lingual caries, extending clinically beyond ¼ dentin thickness or previously restored.

Primary outcomes:
measure: validity of the two devices
timeFrame: Through study completion, an average of 1 year
Secondary outcomes:
measure: Patients satisfaction between two devices
timeFrame: Through study completion, an average of 1 year
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Faculty of Dentistry
city: Cairo
country: Egypt
facility: Cairo University
Study officials:
affiliation: Lecturer, Conservative dentistry department, Faculty of Dentistry, Cairo University.
name: Rawda Hesham Abd ElAziz, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Krause F, Braun A, Eberhard J, Jepsen S. Laser fluorescence measurements compared to electrical resistance of residual dentine in excavated cavities in vivo. Caries Res. 2007;41(2):135-40. doi: 10.1159/000098047.
Clinical trial NCT04225182: Evaluation of the Effectiveness of a Muscular Strengthening Protocol With an Instrumented Orthosis for Gonarthrosis Patients
Official title: Evaluation of the Effectiveness of a Muscular Strengthening Protocol With an Instrumented Orthosis for Gonarthrosis Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Gonarthrosis
Lead sponsor: Centre Hospitalier Universitaire de Nice
Sponsor class: OTHER
First posted: 2020-01-13
Enrollment: 65
Sex: ALL
Minimum age (years): 50
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The management of knee osteoarthritis via a physical activity protocol for rehabilitation has convincing results. However, the effectiveness of these protocols could be improved with a connected instrumented knee brace with an exercise protocol adapted for the patient which is supervise by an online physiotherapist to check the progression during home-based rehabilitation.

Detailed description: The management of knee osteoarthritis via physical activity protocol for rehabilitation has convincing results. The aim of this study is to determine the improvement of the effectiveness of a home-based rehabilitation with and without instrumented knee brace for moderated gonarthrosis patients.

The study will focus during one years on 80 moderated gonarthrosis patients with a Kellgren and Lawrence (K\&L) score between 2 and 3, aged between 50 and 80. Each patient will practice an 8 weeks progressive home exercise program with 3 session per weeks. The effectiveness of this protocol will be quantified with a gait analysis with kinematics, kinetics and electromyography, before and after the progressive home exercise protocol. The statistical analysis will focus on ANOVA and correlation between control group and instrumented knee brace group.

Eligibility criteria: Inclusion Criteria:

* Person who signed informative consent
* Affiliated with the social security
* Male and female aged between 50 and 80
* Walk without assistance
* Smartphone's use

Exclusion criteria:

* Person under protective measure
* Orthopedics issues
* Neurologic issues (MMSE Test \< 24)
* Knee or hip prothesis
* Person with NSAIDs and analgesics treatment with an effective intake less than 48 hours before the evaluation
* Predominant patello-femoral arthritis
* Symptomatic hip OA
* Knee infection
* Knee injuries

Primary outcomes:
measure: Change External Knee Moment Abduction (EKAM) during gait cycle from baseline at 8 weeks after rehabilitation
timeFrame: At the baseline (inclusion) and after 8 weeks of muscular strengthening
Secondary outcomes:
Other outcomes:
Locations:
city: Nice
country: France
facility: CHU de Nice
Study officials:
affiliation: Nice University Hospital
name: Olivier GUERIN, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01944982: Salvage Therapy With Chemotherapy and Natural Killer Cells in Relapsed/Refractory Paediatric T Cell Lymphoblastic Leukaemia and Lymphoma
Official title: Salvage Therapy With Chemotherapy and Natural Killer Cells in Relapsed/Refractory Paediatric T Cell Lymphoblastic Leukaemia and Lymphoma.
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
PHASE2
Conditions: Relapsed/Refractory Paediatric T Cell Lymphoblastic Leukaemia and Lymphoma
Keywords: Immunotherapy
NKAEs
Expanded haploidentical natural killer cells
Activated natural killer cells
Lead sponsor: Hospital Infantil Universitario Niño Jesús, Madrid, Spain
Sponsor class: OTHER
First posted: 2013-09-18
Enrollment: 7
Sex: ALL
Maximum age (years): 21
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To determine safety profile of immunotherapy with natural killer cells and activated expanded (NKAEs) after salvage chemotherapy in relapsed/refractory paediatric T cell lymphoblastic leukaemia and lymphoma.


Eligibility criteria: Inclusion Criteria:

* Patients aged between 0 and 21 years with relapsed or refractary acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma.
* Lansky Index \> 60%.
* Left ventricular ejection fraction \> 39%.
* Negative HIV serology.
* Provide informed consent in accordance with current legislation.

Exclusion Criteria:

* Patients with a history of poor compliance.
* Patients not valid after psycho-social evaluation
* Severe (4) functional organ disorders (hepatic, renal, respiratory) according to NCI CTCAE v3 criteria

Primary outcomes:
measure: Safety profile (number of AEs per patient)
timeFrame: Two months
Secondary outcomes:
measure: Incidence of episodes of febrile neutropenia, bacteriemia or viral or fungal infections
timeFrame: During 14 months
measure: time to hematological recovery (days)
timeFrame: 2 months
measure: days of hospitalization in each cycle
timeFrame: 2 months
measure: Objective response rate
timeFrame: 2 months
measure: days of isolation
timeFrame: 2 months
Other outcomes:
Locations:
city: Madrid
country: Spain
facility: Pediatric Hematology-Oncology; Hospital Infantil Universitario La Paz
Study officials:
affiliation: Service of Pediatric Hematology-Oncology
name: Antonio Pérez-Martínez, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Vela M, Corral D, Carrasco P, Fernandez L, Valentin J, Gonzalez B, Escudero A, Balas A, de Paz R, Torres J, Leivas A, Martinez-Lopez J, Perez-Martinez A. Haploidentical IL-15/41BBL activated and expanded natural killer cell infusion therapy after salvage chemotherapy in children with relapsed and refractory leukemia. Cancer Lett. 2018 May 28;422:107-117. doi: 10.1016/j.canlet.2018.02.033. Epub 2018 Feb 23.
Clinical trial NCT05859282: Development and Validation of a Short Tool to Assess the Awareness of Pregnancy-induced Hypertension
Official title: Development and Validation of a Short Tool to Assess the Awareness of Pregnancy-induced Hypertension: A Cross-sectional Study Among Pregnant Women in Lebanon
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pregnancy Related
Hypertension in Pregnancy
Lead sponsor: Lebanese University
Sponsor class: OTHER
First posted: 2023-05-15
Enrollment: 135
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Pregnant women were targeted from five obstetrics and gynecology clinics.

Brief summary: Background: Pregnancy-induced hypertension (PIH) is responsible for most perinatal and fetal mortality. Few programs are patient-centered during pregnancy, increasing the risks of misinformation and misconceptions among pregnant women and, as a result, malpractices. Objective: This study aims to develop and validate a form to assess the knowledge and attitudes of pregnant women about PIH.

Detailed description: Many observational studies explored the awareness of pregnant women of PIH, but no structured tool is available to assess such awareness. During the past two years, education campaigns were postponed and primary care was prioritized. To allow better-informed decisions and targeted actions, this pilot study aims to develop and validate a short form to assess the knowledge and attitudes of pregnant women about pregnancy-induced hypertension. The long-term objective of this study is to provide a practical tool for pregnant women.

Eligibility criteria: Inclusion Criteria:

* Participants were asked to participate in the study with no criteria based on race, ethnicity, or gestational age.

Exclusion Criteria:

* Those with a history of hypertension or pre-eclampsia were excluded.

Primary outcomes:
measure: Awareness of hypertensive disorders of pregnancy by developing a 25-item questionnaire
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Beirut
country: Lebanon
facility: Lebanese University Faculty of pharmacy
Study officials:
References:
Clinical trial NCT03976882: Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Subjects With Malignancy.
Official title: Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Hetrombopag in Subjects With Chemotherapy-induced Thrombocytopenia Receiving Chemotherapy for the Treatment of Solid Tumors.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Chemotherapy-Induced Thrombocytopenia
Lead sponsor: Jiangsu HengRui Medicine Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2019-06-06
Enrollment: 129
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Hetrombopag compared with placebo
Primary purpose: TREATMENT

Brief summary: Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Hetrombopag in subjects with chemotherapy-induced thrombocytopenia receiving chemotherapy for the treatment of solid tumors.


Eligibility criteria: Inclusion Criteria:

1. Men and women, 18-75 years of age;
2. Participant with a confirmed diagnosis of solid tumor receiving a chemotherapy regimen;
3. Participant experienced thrombocytopenia and chemotherapy delay;
4. ECOG performance status 0-1;

Exclusion Criteria:

1. Screening and baseline platelet count\< 30×109/L;
2. Participant has experienced thrombocytopenia due to any etiology other than chemotherapy within 6 months of screening;
3. Participant has any history of hematologic diseases other than chemotherapy-induced thrombocytopenia;
4. Participant has serious bleeding symptoms;
5. Participant has no hepatic metastases, ALT/AST\>3ULN, TBIL\>3ULN; with hepatic metastases, ALT/AST≥5ULN, TBIL≥5ULN;
6. Blood Cr≥1.5ULN or eGFR≤60 ml/min（Cockcroft-Gault）;
7. History of allergy to the study drug;
8. Participant with HIV;
9. Pregnant or lactating women;
10. Other conditions that may affect participant's safety or trial evaluations per investigator's discretion

Primary outcomes:
measure: The proportion of treatment responders.
timeFrame: Randomization up to 90 days
Secondary outcomes:
measure: Duration from starting treatment to initiating chemotherapy and platelet count ≥100×109/L
timeFrame: Randomization up to 30 days
measure: Proportion of subjects who can completion chemotherapy without rescue therapy and dose modification
timeFrame: Randomization up to 150 days
measure: Proportion of subjects without serious bleeding event
timeFrame: Randomization up to 180 days
measure: Number of subjects with any Adverse Event (AE) or Serious Adverse Event (SAE) graded by the investigator according to National Cancer Institute (NCI) Common Terminology Criteria for AEs (CTCAE), version 5.0
timeFrame: Randomization up to 180 days
Other outcomes:
Locations:
city: Nanjing
country: China
facility: Najing Bayi Hospital
state: Jiangsu
Study officials:
References:
Clinical trial NCT02085382: Randomized, Controlled Trial of Kangaroo Mother Care in Increasing the Rate of Weight Gain Among Neonates
Official title: A Randomized, Controlled Trial of Kangaroo Mother Care in Increasing the Rate of Weight Gain Among Low Birth Weight Neonates Admitted in Level II Neonatal Intensive Care Unit of the Philippine General Hospital
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Low Birth Weight Among Neonates
Keywords: Kangaroo Mother Care(KMC), Low-birth weight, neonates
Lead sponsor: University of the Philippines
Sponsor class: OTHER
Collaborators: name: Pfizer
First posted: 2014-03-12
Enrollment: 52
Sex: ALL
Minimum age (years): 1
Maximum age (years): 28
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: A randomized, controlled trial of Kangaroo Mother Care (KMC) to determine the effectiveness in increasing the rate of weight gain among low birth weight neonates.

Detailed description: A randomized, controlled trial of Kangaroo Mother Care (KMC) versus Conventional Care to determine the effectiveness of KMC in increasing the rate of weight gain among low birth weight neonates and if it will decrease sepsis rate and shorten hospital stay among the group.

Eligibility criteria: Inclusion Criteria:

* birth weight \<1500 grams and stable neonates (no dependency on oxygen and /or intravenous fluid, ability (at least partial) to feed) with stable vital signs for the past 24 hours (normal temperature (36.5-37.5 °C),
* normal heart rate (120-160 bpm), normal blood pressure per age
* no apnea
* no intravenous lines or with well-secured peripheral line
* no sepsis
* no emerging signs of sepsis
* on IV antibiotic therapy but clinically stable
* can require photo therapy but with stable and not rising total serum bilirubin (TSB) level or TSB is not in high risk zone.

Exclusion Criteria:

* neonates with chromosomal and life threatening congenital anomalies, who were severally ill
* whose mothers are critically ill and whose mothers were unable to comply with the follow up schedule.

Primary outcomes:
measure: Low Birth Weight
timeFrame: 3 days
Secondary outcomes:
Other outcomes:
Locations:
city: Manila
country: Philippines
facility: Philippine General Hospital - University of the Philippines Manila
state: National Capital Region
Study officials:
affiliation: Department of Pediatrics College of Medicine
name: Faye S De Ocampo, Medical Doctor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01843582: A Study to Determine the Location of the Blind Spot and the Macula-disc Centre Distance on a Fundus Photograph
Official title: A Study to Develop Both a Novel Method for Evaluating the True Size of a Retinal Object on Fundus Photographs and a New Reaction-time Based Method for Studying the Visual Field on Healthy Volunteers
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Generalized Visual Field Contraction or Constriction
Keywords: Keyword: blind spot
Lead sponsor: Turku University Hospital
Sponsor class: OTHER_GOV
First posted: 2013-04-30
Enrollment: 17
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Healthy volunteers

Brief summary: The study is aimed to develop a new reaction-time based method for examining the visual field and to study the effect of refractive error on the magnification of a fundus photograph in order to evaluate the true size of a retinal feature.


Eligibility criteria: Inclusion Criteria:

* No disease that effect the fundus photograph or visual field

Exclusion Criteria:

* any disease that effects the fundus photograph or visual field

Primary outcomes:
measure: Macula-disc centre distance
timeFrame: one measurement at the start of the study
Secondary outcomes:
measure: Location of the blind spot
timeFrame: one measurement at the start of the study
Other outcomes:
Locations:
city: Turku
country: Finland
facility: Turku University Hospital
Study officials:
affiliation: Turku University Hospital
name: Eija Vesti, professor
role: STUDY_DIRECTOR
References: